Scholarlink

<p>While intestinal stem cells (ISC) are essential for epithelial homeostasis, their dynamic regulation during immune-mediated injury remains undefined. Here we show that suppression of jejunal ISC proliferation contributes to pathology arising from oral EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) treatment. Suppression of adaptive immunity via genetic intervention reverses ISC suppression and accelerates mucosal repair via inhibiting the TKI-induced, chemokine-directed migration of T and B lymphocytes from Peyer’s patches. Spatial transcriptomics reveals enhanced crosstalk between adaptive immune cells and ISCs in the jejunum. Ex vivo modelling demonstrates that activated T cells directly impair ISC survival through IFN-γ and TNF, with IFN-γ-induced JAK (Janus kinase) /STAT signaling serving as a critical downstream effector. Accordingly, targeted JAK inhibition mitigates EGFRi (epidermal growth factor receptor inhibitor)–induced diarrhea without substantially compromising antitumor efficacy. This work thus redefines TKI-induced enteropathy as an immune-driven pathology and identifies JAK inhibition as a mechanism-based supportive management of targeted therapy toxicities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

JAK inhibitors alleviate EGFR-inhibitor-induced diarrhea by protecting intestinal stem cells from adaptive-immune-exacerbated injury

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月13日

查看全文
  • Yuan Cheng,
  • Chenyue Xu,
  • Dazhao Lv,
  • Meng Tian,
  • Haoyu Wang,
  • Bingxue Yang,
  • Leying Chen,
  • Qing You,
  • Shiyi Zhang

摘要

While intestinal stem cells (ISC) are essential for epithelial homeostasis, their dynamic regulation during immune-mediated injury remains undefined. Here we show that suppression of jejunal ISC proliferation contributes to pathology arising from oral EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) treatment. Suppression of adaptive immunity via genetic intervention reverses ISC suppression and accelerates mucosal repair via inhibiting the TKI-induced, chemokine-directed migration of T and B lymphocytes from Peyer’s patches. Spatial transcriptomics reveals enhanced crosstalk between adaptive immune cells and ISCs in the jejunum. Ex vivo modelling demonstrates that activated T cells directly impair ISC survival through IFN-γ and TNF, with IFN-γ-induced JAK (Janus kinase) /STAT signaling serving as a critical downstream effector. Accordingly, targeted JAK inhibition mitigates EGFRi (epidermal growth factor receptor inhibitor)–induced diarrhea without substantially compromising antitumor efficacy. This work thus redefines TKI-induced enteropathy as an immune-driven pathology and identifies JAK inhibition as a mechanism-based supportive management of targeted therapy toxicities.